{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:02:20Z","timestamp":1782824540286,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006521","name":"School of Medicine, Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bbmt.2020.08.035","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T02:48:34Z","timestamp":1600483714000},"page":"e328-e332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents"],"prefix":"10.1016","volume":"26","author":[{"given":"Christopher","family":"Lemieux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana K.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.08.035_bib0001","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1002\/cncr.24700","article-title":"Primary plasma cell leukemia","volume":"115","author":"Ramsingh","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0002","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3324\/haematol.2009.013334","article-title":"Primary plasma cell leukemia and autologous stem cell transplantation","volume":"95","author":"Drake","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0003","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0004","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","article-title":"t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome","volume":"37","author":"An","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.23600","article-title":"Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0006","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0007","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdq646","article-title":"Primary plasma cell leukemia: a retrospective multicenter study of 73 patients","volume":"22","author":"Pagano","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0008","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2013.12.557","article-title":"Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma","volume":"20","author":"Saad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0010","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0011","doi-asserted-by":"crossref","unstructured":"Dhakal B, Patel S, Girnius S, et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. doi: 10.1038\/s41375-020-0830-0, accessed April 17, 2020. [e-pub ahead of print].","DOI":"10.1038\/s41375-020-0830-0"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0012","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41409-020-0887-4","article-title":"Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation","volume":"55","author":"Costa","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0013","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41409-018-0392-1","article-title":"Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs","volume":"54","author":"Gowda","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0014","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.bbmt.2020.08.035_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8509","article-title":"Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"38","author":"Kumar","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl_1","key":"10.1016\/j.bbmt.2020.08.035_bib0017","article-title":"Phase I\/II study evaluating the safety and efficacy of venetoclax in combination with dexamethasone as targeted therapy for patients with t(11;14) relapsed\/refractory multiple myeloma","volume":"134","author":"Kaufman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0018","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating Bcl-2 inhibition with venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.08.035_bib0019","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/1078155219895072","article-title":"A successful case of venetoclax-based therapy in relapsed\/refractory secondary plasma cell leukemia","volume":"26","author":"Kupsh","year":"2020","journal-title":"J Oncol Pharm Pract"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:07Z","timestamp":1761059587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120305838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1083879120305838"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.035","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}